• Skip to primary navigation
  • Skip to main content
  • Skip to primary sidebar
  • Skip to footer
  • Advertise
  • Subscribe

MassDevice

The Medical Device Business Journal — Medical Device News & Articles | MassDevice

  • Latest News
  • Technologies
    • Artificial Intelligence (AI)
    • Cardiovascular
    • Orthopedics
    • Neurological
    • Diabetes
    • Surgical Robotics
  • Business & Finance
    • Wall Street Beat
    • Earnings Reports
    • Funding Roundup
    • Mergers & Acquisitions
    • Initial Public Offering (IPO)
    • Legal News
    • Personnel Moves
    • Medtech 100 Stock Index
  • Regulatory & Compliance
    • Food & Drug Administration (FDA)
    • Recalls
    • 510(k)
    • Pre-Market Approval (PMA)
    • MDSAP
    • Clinical Trials
  • Special Content
    • Special Reports
    • In-Depth Coverage
    • DeviceTalks
  • Podcasts
    • MassDevice Fast Five
    • DeviceTalks Weekly
    • OEM Talks
      • AbbottTalks
      • Boston ScientificTalks
      • DeviceTalks AI
      • IntuitiveTalks
      • MedtechWOMEN Talks
      • MedtronicTalks
      • Neuro Innovation Talks
      • Ortho Innovation Talks
      • Structural Heart Talks
      • StrykerTalks
  • Resources
    • About MassDevice
    • DeviceTalks
    • Newsletter Signup
    • Leadership in Medtech
    • Manufacturers & Suppliers Search
    • MedTech100 Index
    • Videos
    • Webinars
    • Whitepapers
    • Voices
Home » NuVasive keeps clawing back

NuVasive keeps clawing back

September 27, 2011 By MassDevice staff

NuVasive

Shares of NuVasive Inc. (NSDQ:NUVA) are clawing their way back from a 52-week low posted after the company lost a $100 million lawsuit against Medtronic Inc. (NYSE:MDT).

A federal jury in San Diego last week awarded $101.2 million to Medtronic in a patent infringement lawsuit involving spinal implant technology.

The news sent NUVA shares down the chute, from $21.21 before the jury’s decision to a Sept. 21 close of $18.65, a loss of more than 12 percent.

Sign up to get our free newsletters delivered straight to your inbox

But NUVA shares opened at $20.50 this morning on The Street, up 1.5 percent on the day and more than 14.7 percent above their 52-week nadir of $17.87.

The upswing coincides with a raft of differing views on the company among Wall Street analysts. Analysts at JPMorgan Chase & Co. (NYSE:JPM) cut their price target to $24 Sept. 22, according to LocalizedUSA.com, and researchers at Piper Jaffray (NYSE:PJC) held to their “overweight” rating the next day. Investment bank Barclay’s decided the same day to initiate coverage of NuVasive with an “overweight” rating and a price target of $25. Jefferies lowered its price target to $30 yesterday.

A federal jury in San Diego awarded $101.2 million to Medtronic and $660,000 to its smaller rival Tuesday in a patent infringement lawsuit over spinal implant technology. The news prompted at least one analyst on The Street to lower his earnings estimate for NuVasive’s 2011 and 2012 fiscal years “to account for ongoing MDT royalty accruals.”

“In the near-term, uncertainty around the exact amount of royalties and/or the possibility that MDT will seek an injunction may keep NUVA shares under pressure – at least until a final judgment is issued,” Leerink Swann analyst Rick Wise wrote, noting that it’s only the first phase of a three-stage trial. “However, now that the financial impact of this first, and in our view more significant, phase of the trial has – at least partially – been framed, we think the stock is poised to move higher from currently depressed levels as: (1) we get increased clarity that royalties are not likely to be materially worse than the company’s initial estimates, and (2) investors begin to re-focus on the company’s above-average sales growth potential.”

Wise maintained the investment bank’s “Outperform” rating on the stock, but cut earnings-per-share estimates for 2011 to $1.06, from $1.11, and lowered the 2012 EPS forecast from $1.27 to $1.15.

Filed Under: News Well, Wall Street Beat Tagged With: Nuvasive

More recent news

  • Data backs DermaSensor skin cancer detection device
  • GE HealthCare expands digital imaging portfolio with enhanced MIM Encore software
  • Accelus wins FDA clearance for MRI compatibility of FlareHawk spinal implants
  • Presidio wins FDA IDE for ultra-low frequency neuromod, hires new CFO
  • Epiminder study backs implantable EEG tech

Primary Sidebar

“md
EXPAND YOUR KNOWLEDGE AND STAY CONNECTED
Get the latest med device regulatory, business and technology news.

DeviceTalks Weekly

See More >

MEDTECH 100 Stock INDEX

Medtech 100 logo
Market Summary > Current Price
The MedTech 100 is a financial index calculated using the BIG100 companies covered in Medical Design and Outsourcing.
MDO ad

Footer

MASSDEVICE MEDICAL NETWORK

DeviceTalks
Drug Delivery Business News
Medical Design & Outsourcing
Medical Tubing + Extrusion
Drug Discovery & Development
Pharmaceutical Processing World
MedTech 100 Index
R&D World
Medical Design Sourcing

DeviceTalks Webinars, Podcasts, & Discussions

Attend our Monthly Webinars
Listen to our Weekly Podcasts
Join our DeviceTalks Tuesdays Discussion

MASSDEVICE

Subscribe to MassDevice E-Newsletter
Advertise with us
About
Contact us

Copyright © 2025 · WTWH Media LLC and its licensors. All rights reserved.
The material on this site may not be reproduced, distributed, transmitted, cached or otherwise used, except with the prior written permission of WTWH Media.

Privacy Policy